Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada

Posted by Kyle Jackson on Jul 11th, 2026

Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price target raised by Royal Bank Of Canada from $30.00 to $33.00 in a research note released on Friday morning, Marketbeat Ratings reports. The firm currently has an outperform rating on the stock.

Several other brokerages have also weighed in on NRIX. Oppenheimer initiated coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They set an “outperform” rating and a $28.00 price objective on the stock. Wells Fargo & Company lowered Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their target price for the stock from $28.00 to $25.00 in a research report on Monday, June 8th. Jefferies Financial Group boosted their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Robert W. Baird upped their price objective on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Truist Financial lifted their price objective on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, June 8th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $33.77.

Check Out Our Latest Stock Analysis on NRIX

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded down $1.63 during trading on Friday, hitting $23.06. The company’s stock had a trading volume of 1,552,950 shares, compared to its average volume of 2,287,902. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -7.30 and a beta of 1.80. Nurix Therapeutics has a 52 week low of $8.19 and a 52 week high of $25.08. The stock has a 50-day moving average price of $18.44 and a two-hundred day moving average price of $17.37.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Nurix Therapeutics had a negative return on equity of 73.57% and a negative net margin of 928.44%.The firm had revenue of $9.04 million for the quarter, compared to the consensus estimate of $15.29 million. On average, equities analysts predict that Nurix Therapeutics will post -2.88 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the sale, the insider directly owned 115,005 shares in the company, valued at $2,300,100. The trade was a 4.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. The trade was a 27.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,051 shares of company stock valued at $434,466 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC grew its position in shares of Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Nurix Therapeutics during the 4th quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Nurix Therapeutics during the 4th quarter worth approximately $33,000. KBC Group NV bought a new stake in shares of Nurix Therapeutics in the 1st quarter worth approximately $34,000. Finally, Wexford Capital LP purchased a new position in Nurix Therapeutics in the third quarter valued at approximately $41,000.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.